Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus
verfasst von:
Bipin Sethi, A. G. Unnikrishnan, Vageesh Ayyar, P. K. Jabbar, K. K. Ganguly, Sudhir Bhandari, Ashu Rastogi, Rajarshi Mukherjee, Vivek Sundaram, Adlyne R. Asirvatham
This systematic review aims to present the current evidence base with respect to the initiation and intensification of insulin therapy with glargine 100 U/mL (Gla-100) compared to other insulins in people with type 2 diabetes mellitus (T2DM).
Methods
A systematic literature search of PubMed (MEDLINE), EMBASE, and the Cochrane Central Register of controlled clinical trials databases was performed to identify studies published up to September 30, 2020 that compared the effects of Gla-100 to that of other insulin regimens in people with T2DM. Relevant information pertaining to the predefined outcomes of interest was extracted. Glycated hemoglobin (HbA1c) change and response rates along with overall hypoglycemia incidence were the primary efficacy and safety outcomes of interest.
Results
Seventy-nine studies (63 interventional and 16 non-interventional) in which Gla-100 was either initiated in previously insulin-naïve patients (n = 57) or used in an intensified regimen (n = 22) were identified and evaluated. In insulin-naïve patients, most studies demonstrated that Gla-100 was significantly better compared with premixed insulins and similar compared with neutral protamine Hagedorn (NPH) insulin, second-generation basal insulins, co-formulations, and other first-generation basal insulins in terms of the primary efficacy parameters. Overall hypoglycemia risk with Gla-100 was significantly lower compared with NPH, premixed, coformulation, and other first-generation basal insulins and significantly higher compared with second-generation basal insulins. In studies with intensified regimens, efficacy outcomes with Gla-100 were significantly better compared with insulin detemir (IDet); similar compared with NPH, second-generation basal insulins, co-formulations; and with premixed insulins. In these studies, overall hypoglycemia risk with Gla-100 was significantly lower compared with IDet and comparable to NPH, premixed insulins, co-formulations, and second-generation basal insulins. In addition, most intensification studies also revealed a significantly lower risk of nocturnal hypoglycemia with Gla-100–based regimens versus NPH and premixed insulins and a significantly greater risk compared to second-generation basal insulins.
Conclusions
The evidence presented in this review suggests that Gla-100 is an effective option for both insulin initiation and intensification strategies used in the management of T2DM.
This review highlights the efficacy and safety of Gla-100 in comparison to other insulin preparations in initiation and intensification strategies in type 2 diabetes mellitus (T2DM).
Initiation of Gla-100 in insulin-naïve patients with T2DM failing oral therapies resulted in better glucose-lowering outcomes than premixed insulins and showed comparable results to neutral protamine Hagedorn (NPH), second-generation basal insulins, co-formulations, as well as other first-generation basal insulins.
Most of the studies showed that Gla-100 initiation in insulin-naïve people with T2DM is associated with a lower risk of overall hypoglycemic events compared to other insulin molecules except for second-generation basal insulins.
Intensification of insulin therapy with Gla-100-based regimens in most of the studies showed significantly better glucose-lowering outcomes against insulin detemir (IDet), comparable results to NPH, second-generation basal insulins, co-formulations, and against premixed insulins.
Most of the Gla-100 intensification studies showed comparable overall hypoglycemia risk with all other insulin regimens, but a significantly lower risk of nocturnal hypoglycemia vs. NPH and premixed insulins and a significantly greater risk compared to second-generation basal insulins.
Introduction
The strategy of using insulin basal analogue as an add-on to oral anti-diabetic drugs (OADs) was introduced with the intention of optimizing glycemic control and minimizing hypoglycemia and weight gain associated with other existing insulin molecules [1]. Insulin glargine 100 U/mL (Gla-100) was the first basal analog to be approved in 2000 [1]. Ever since its approval, Gla-100 has become one of the most widely studied basal insulin therapies globally, and has emerged as the reference basal insulin to which newer basal insulins are compared [1, 2]. Despite a strong evidence base accumulated from clinical trials as well as real-world studies over the course of two decades, there still exists certain ambiguity over the position of Gla-100 within the insulin landscape.
Anzeige
There is a dearth of systematic reviews that evaluate efficacy and safety of Gla-100 as an initiation therapy in insulin-naïve patients or in those who switched to Gla-100 after being on other insulin regimens. Furthermore, data on the current update with regard to the use of Gla-100 in treatment intensification strategies is scarce in people with T2DM. Therefore, with the purpose of evaluating efficacy and safety of Gla-100 in comparison to other insulin preparations in initiation and intensification strategies, this systematic review aims to shed a light on this voluminous evidence with Gla-100 and will present the evidence to address key questions on the use of Gla-100 from a clinician’s perspective. This review will compare Gla-100 with different types of insulin analogs and summarize the glycemic outcomes (glycated hemoglobin [HbA1c] reduction, response rates, blood glucose [BG] profile, and glycemic variability) and safety outcomes (hypoglycemic events, weight change and insulin dose change, and treatment satisfaction).
Methods
Search Strategy
The preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and the methods for systematic reviews as specified by the National Institute for Health and Care Excellence (NICE) in Sect. 2.1 of the Single Technology Appraisal (STA) user guide [3] were followed to identify the clinical evidence through a systematic search of major bibliographic databases. PubMed (MEDLINE), EMBASE, and the Cochrane Central Register of controlled trials databases were separately searched for studies published up to September 30, 2020 in order to identify all publications that compared the effects of the administration of Gla-100 to that of other insulin regimens in patients with T2DM. The following search terms were used in combination with appropriate MeSH terms and Boolean operators (e.g., ‘and’, ‘or’, ‘not’): insulin, basal insulin, glargine, U-100, long-acting insulin, insulin analog, type 2 diabetes, and T2DM. The search was not restricted by any time period; however, the language of publication was restricted to English (See Table S1 in the electronic supplementary material for detail). This article is based on previously conducted studies and does not contain any new studies with human participants or animals.
Inclusion and Exclusion Criteria
The inclusion criteria of the present systematic review were as follows: (i) adult people (age ≥ 18 years) with T2DM either initiating Gla-100 (insulin-naïve patients) or patients switching from other insulin regimens to Gla-100; (ii) studies that compared the effects of the administration of other insulins (premixed, co-formulations, and second-generation basal insulins) with that of Gla-100; (iii) studies that reported reduction in HbA1c, fasting blood glucose (FPG), postprandial blood glucose levels (PPG), weight gain or the proportion of patients achieving targets; hypoglycemic events or increase in insulin dose; (iv) studies conducted as randomized controlled trial (RCT), non-randomized controlled trial or comparative studies, observational studies (prospective or retrospective design), case–control studies and cross-sectional studies with ≥ 50 patients and (v) study duration of a minimum of 3 weeks. Furthermore, studies for treatment initiation were included and segregated into those with insulin-naïve patients and those with patients who were inadequately controlled on OADs and had to be treated with insulin or combination of OADs with insulin. For insulin intensification studies, patients switching to a basal-bolus or any other regimen, including biphasic or premixed insulins with Gla-100 as a component, were considered eligible.
The exclusion criteria were as follows: (i) studies enrolling people with type 1 diabetes mellitus (T1DM) or other diseases or a mixed population of patients with both T1DM and T2DM were excluded unless separate subgroup data was presented for people with T2DM; (ii) single-arm studies or studies comparing the effects of Gla-100 with OADs or any injectable therapy other than insulin; (iii) case reports, letters to editors, abstracts, or proceedings of scientific meetings; and (iv) studies published in non-English language.
Anzeige
Screening of Eligible Studies
All references identified through literature searches were imported and duplicates were removed to evaluate the study for full-text eligibility. The study selection was instrict compliance with the pre-determined inclusion and exclusion criteria. Each of the retrieved documents was assessed for eligibility as per the selection process detailed in Fig. 1.
Fig. 1
PRISMA flow diagram
×
Outcomes
The outcomes of interest in this study varied on the basis of study type. For RCTs, the main outcomes were reduction in HbA1c, change in FPG, PPG, and response rates. Similarly, HbA1c reduction and response rates were the main outcomes of interest for observational studies. Other outcomes of interest irrespective of study type were rate of hypoglycemic events (nocturnal or overall), percentage weight gain, and change in insulin dose from baseline to the end of study. Among all the aforementioned outcomes, HbA1c change and response rates were the primary glycemic outcomes of interest and overall hypoglycemic events were the primary safety outcomes of interest.
Data Extraction
A predefined data extraction grid was developed in Microsoft Excel to extract data on study characteristics and outcomes. All relevant information from the eligible studies was extracted, which included study design, study duration, country, sample size, comorbid conditions, previous treatments, change in clinical parameters (including HbA1c, FPG, PPG, weight), changes in insulin regimen, as well as safety outcomes (hypoglycemic events); and their corresponding p values and 95% confidence interval (CI), whenever reported.
Quality Assessment
The quality of observational studies (cohort/cross-sectional studies) was assessed by using Newcastle–Ottawa Scale (NOS), whereas the quality of RCTs was assessed using the Cochrane Risk of Bias tool (CRBT) [4, 5].
Results
Study Search
As shown in the study flow diagram (Fig. 1), the search yielded 13,942 hits; of which 79 studies were included in the final list for data extraction, including 63 interventional and 16 non-interventional studies. There were 57 studies (Table 1) wherein Gla-100 was initiated in either insulin-naïve or previously Gla-100 -naïve patients [6‐62]and 22 studies (Table 2) wherein Gla-100 was used in an intensified regimen [63‐85].
Seq A—Gla-100 OD + MET followed by lispro mix 75/25 BD; 47
59.63 (8.03)
29 (62.0)
11.9 (6.27)
Seq B—lispro mix 75/25 BD + MET followed by Gla-100 OD; 50
59.18 (8.58)
25 (50.0)
13.52 (8.18)
BD twice daily, Gla-100 glargine-100, IDeg insulin degludec, MET metformin, NPH neutral protamine Hagedorn, OADs oral anti-diabetics, OD once daily, RCT randomized clinical trial, SU sulfonylurea, TID thrice a day
aStudy duration in months categorization was done for the ease of interpretation; however, actual study duration is specified in the brackets
Table 2
Summary of included studies (intensification)
Author (year)
Study design
Study duration in months (weeks)a
Intervention
Age (years), mean (SD)
Sex (female), N (if available) (%)
Disease duration (years), mean (SD)
Duration of prior insulin therapy (years), mean (SD)
IDet OD + aspart + OADs (minus secretagogues and α-glucosidase inhibitors); 214
59
84 (39.3)
13.6
–
Gla-100 OD + aspart + OADs (minus secretagogues and α-glucosidase inhibitors); 105
58
50 (47.6)
13.4
–
BD twice daily, IDeg insulin degludec, Gla-100 glargine-100, MET metformin, NPH neutral protamine Hagedorn, OADs oral anti-diabetics, OD once daily, RCT randomized clinical trial, SU sulfonylurea, TID thrice a day, TZDs thiazolidinediones
aStudy duration in months categorization was done for the ease of interpretation; however, actual study duration is specified in the brackets
Study and Patient Characteristics
Initiation
In the 57 studies reporting the results of efficacy and safety of insulin initiation, the mean HbA1c level at baseline was > 8% with values ranging from 7.55 [6] to 10.3% [7]. The mean (SD) baseline FPG value ranged from 133.2 (34.2) mg/dL [8] to 194.4 mg/dL [9], whereas the baseline PPG value was reported in only five studies and ranged from 205.2 (61.2) mg/dL [10] to 363.78 (110.34) mg/dL [11]. Similarly, the mean (SD) bodyweight of included patients ranged from 61.9 (9.29) kg [12] to 108 (25.7) kg [13] (Table 3) [6‐62].
BD bi-daily, DPP-4 dipeptidyl peptidase-4, IDeg insulin degludec, Gla-100 glargine-100, Gla-300 glargine-300, MET metformin, NPH neutral protamine Hagedorn, OADs oral anti-diabetics, OD once daily, RCT randomized clinical trial, SU sulfonylurea, TID thrice a day, TZDs thiazolidinediones
The most frequently used insulin analogs were Gla-100, NPH insulin, insulin degludec (IDeg), insulin lispro 75/25 mix and premixed insulins. The mean (SD) recorded baseline insulin dose varied from 0.11 (0.02) U/kg/day [53] to 77.6 (32.1) U/kg/day [34]. Several studies evaluated the efficacy and safety profile of Gla-100 given with one or more OAD therapy (such as acarbose, glimepiride, metformin [MET], sulphonylurea [SU]) to determine the best analog for initiation of insulin therapy among insulin-naïve patients.
Intensification
In the 22 studies reporting the results of efficacy and safety of insulin intensification with a basal or biphasic insulin regimen, the mean HbA1c level at baseline in majority of the studies was between 8 and 9% with values ranging from 8.0 (0.9) [63] to 9.5 (1.2) [67]. Out of the 22 studies, only nine reported mean (SD) baseline FPG values that ranged from 108 (28.8) mg/dL [65] to 207 (75.6) mg/dL [66], whereas the baseline PPG value was reported in three studies [67‐69]. Similarly, the mean (SD) body weight of included patients ranged from 69.3 (15.1) kg [70] to 106.4 (20) kg [71] (Table 4).
IDet OD + aspart + OADs (minus secretagogues and α-glucosidase inhibitors)
> 12
8.6 (1)
7.19
− 1.52
NS
171 (54)
127
− 46.08
NS
Gla-100 OD + aspart + OADs (minus secretagogues and α-glucosidase inhibitors)
8.8 (1.1)
7.03
− 1.68
176.4 (52.2)
120.2
− 52.56
PPG values were not reported for any of the studies included
BD bi-daily, DPP-4 dipeptidyl peptidase-4, IDeg insulin degludec, Gla-100 glargine-100, Gla-300 glargine-300, MET metformin, NPH neutral protamine Hagedorn, OADs oral anti-diabetics, OD once daily, RCT randomized clinical trial, SU sulfonylurea, TID thrice a day
Besides Gla-100 (either with other insulin or in combination with OADs), the other most frequently used insulins were (NPH insulin, premixed insulin mix or lispro mix. The mean (SD) baseline insulin dose varied from 0.17 (0.03) U/kg/day [74] to 77.65 (48.5) U/kg/day [77]. Several studies reported the efficacy and safety profile of Gla-100 given with either one or more OAD therapy (MET, pioglitazone, SU) or insulin variants (insulin aspart, regular insulin, insulin lispro, insulin degludec-aspart [IDegAsp] or premixed) in order to determine the best treatment strategy using insulin intensification.
Clinical Outcomes
Insulin Initiation
Gla-100 vs. NPH Insulin
Thirteen studies compared Gla-100 with NPH insulin which included use of the insulin doses in combination with OADs [14‐26] (Table 3).
Glycemic Outcomes
Primary Outcomes
HbA1c
Out of 13 studies reporting mean HbA1c reduction, eight studies were of fair-to-good quality; of which two studies reported significantly higher HbA1c reduction in the Gla-100 group than NPH group, and the remaining six studies reported relatively similar HbA1c reduction with both the insulin types [14‐17, 19, 21, 22, 25]. Of the remaining five studies that were of poor quality, three studies reported significant difference in HbA1c reduction favoring Gla-100 use over NPH insulin (P < 0.001–0.03) [18, 20, 26] (Table 3).
Response Rates
Out of eight studies, Gla-100 and NPH did not differ significantly with respect to the proportion of patients achieving target HbA1c (n = 7) and FPG (n = 5) in majority of the studies. However, three studies of fair to poor quality reported significant improvement in response rates of Gla-100 over NPH insulin [20, 22, 25]. Among these fair-to-poor quality studies, Eliaschewitz et al. showed that a higher proportion of patients receiving Gla-100 achieved HbA1c targets without confirmed hypoglycemia (26.8%), when compared to NPH (17.3%) [22]. Insulin Gla-100 appeared to be better than NPH in terms of proportion of patients achieving HbA1c targets with no nocturnal hypoglycemia (33.2 vs. 26.7%, P = 0.05 [25] and 22.9 vs. 14%, P = 0.0174 [20]) and also FPG targets with no nocturnal hypoglycemia (22.1 vs. 15.9%, P < 0.03 [25]) (see Table S2 in the electronic supplementary material for detail).
Safety Outcomes
Primary Outcomes
Hypoglycemic Events
A total of 13 studies reported overall hypoglycemia or nocturnal hypoglycemia. Of these, seven studies, in which Gla-100 was associated with lower incidence of overall hypoglycemic events (P > 0.0001 to > 0.04) [16, 20, 22, 23, 25, 26] and nocturnal hypoglycemia (P < 0.001 to < 0.03) [20, 22‐26] compared to corresponding groups receiving NPH, were of fair-to-poor quality (Table 5).
Gla-100 vs. Premixed Insulins
Twenty studies reported insulin initiation and compared the outcomes between Gla-100 and premixed insulins [7, 10‐13, 27‐41]. In a majority of studies (n = 19), the insulins were co-administered with OADs [7, 10‐13, 27‐37, 39‐41] (Table 3).
Glycemic Outcomes
Primary Outcomes
HbA1c
Out of 20 studies reporting HbA1c reduction, 15 studies belonged to fair-to-good quality. The baseline and endpoint values for HbA1c were similar to the initiation studies reported above. When compared to premixed insulins, HbA1c reduction was reported in 15 of the 20 studies. The HbA1c reduction was significantly higher (P < 0.05) with Gla-100 compared to premixed insulins in 14 out of 20 studies [10, 12, 13, 27, 28, 30‐33, 35‐37, 39, 40] (Table 3).
Response Rates
In the studies reporting response rates (n = 15), six studies showed that the Gla-100 treatment regimen exhibited significant difference with respect to the proportion of patients achieving target HbA1c (P < 0.001–0.038) and FPG levels (P = 0.0002–0.019), when compared to patients on premixed insulin [7, 12, 33, 35, 36, 41]. All of these studies were of fair-to-good quality. However, no statistically significant difference was observed between Gla-100 and premixed insulin regimens pertaining to the proportion of patients achieving HbA1c either with no confirmed hypoglycemia or with no nocturnal hypoglycemia and proportion of patients achieving FPG target with no confirmed nocturnal hypoglycemia or with no nocturnal hypoglycemia (see Table S2 in the electronic supplementary material for details).
Safety Outcomes
Primary Outcomes
Hypoglycemia Events
In the Gla-100 vs. premixed insulin initiation studies (n = 18) reporting hypoglycemia events, six studies with Gla-100 insulin initiation regimen were associated with significantly lower incidence of overall hypoglycemia (P < 0.0001–0.04) and nocturnal hypoglycemia (P = 0.009–0.021) vs. premixed insulin [29, 32, 33, 36, 37, 39]. All of these studies, except one study [37], were of fair-to-good quality (see Table S4 in the electronic supplementary material for details).
Gla-100 vs. Second-Generation Basal Insulins
Overall, 14 insulin initiation studies comparing Gla-100 with second-generation basal insulin treatment regimens in insulin-naïve patients with T2DM were of fair-to-good quality [6, 8, 42‐53] (Table 3).
Glycemic Outcomes
Primary Outcomes
HbA1c
In eight studies, Gla-100 did not differ significantly with respect to HbA1c reduction when compared to IDeg-100 or 200 administered once a day [44‐47, 50‐53]. However, one study exhibited significant reduction in HbA1c levels with Gla-300 when compared with Gla-100 (P = 0.003) [42] (Table 3).
Response rates
In nine studies, Gla-100 treatment did not offer any significant improvements over second-generation basal insulins in any of the response-rate parameters being assessed. Only one study, which was a good-quality study, reported significantly higher proportion of patients achieving target HbA1c in Gla-300 group when compared with Gla-100 group (P = 0.029) [42] (see Table S2 in the electronic supplementary material for details).
Safety Outcomes
Primary Outcomes
Hypoglycemia Events
Out of 13 studies reporting hypoglycaemia, only three studies reported significant difference between Gla-100 and second-generation basal insulins. These studies were of fair-to-good quality [43, 45, 48]. Gla-300 receiving patients exhibited significantly lower overall rate of hypoglycemia when compared with Gla-100 (6.4 vs. 8.5 events/PYE, P = 0.042) [48]. However, in a crossover study, IDeg followed by Gla-100 in combination to OADs led to lesser hypoglycemic events than those receiving Gla-100 followed by IDeg (219.9 episodes vs. 275.1 episodes/ 100 PYE, P < 0.001) [45]. Similarly, no significant difference was observed between the two groups in the rates of nocturnal hypoglycaemia, apart from the abovementioned study where IDeg followed by Gla-100 administration resulted in fewer events than the group receiving Gla-100 followed by IDeg (P < 0.001). In a study by Zinman et al. Gla-100 group reported significantly lower incidence of severe hypoglycemia compared with IDeg group (P = 0.017) [53] (Table 5).
Gla-100 vs. Co-formulations
Only three studies reported the use of Gla-100 with insulin co-formulations [54‐56] and were of fair-to-good quality. These co-formulations consisted of IDegAsp with various OAD combinations (including MET, DPP-4 inhibitor, SU, pioglitazone) (Table 3).
Glycemic Outcomes
Primary Outcomes
HbA1c
No significant difference was reported for HbA1c reductions between the groups receiving Gla-100 and insulin co-formulations in all the three studies [54‐56] (Table 3).
Response Rates
The two groups exhibited a similar number of patients achieving target HbA1c levels. There were no data reported for the number of patients achieving FPG targets [54‐56] (see Table S2 in the electronic supplementary material for details).
Safety Outcomes
Primary Outcomes
Hypoglycemia events
A study by Kumar A et al. reported significant difference (P < 0.0001) and a treatment ratio of 1.86 in favor of Gla-100 [55] for overall and nocturnal hypoglycaemia. Another study by Kumar S et al. reported significantly lower incidence of hypoglycemia in Gla-100 receiving group (48.1 vs. 52.3%, P < 0.05) [54] (Table 5).
Gla-100 vs. Other First-Generation Basal Insulins
Only seven studies evaluated the effect of Gla-100 against other first-generation basal insulins in insulin-naïve patients with T2DM undergoing insulin initiation. Of these, five studies were of good quality [9, 58‐61] and two were of poor quality [57, 62]. A majority of studies (n = 6) compared Gla-100 in combination with OADs against human NPL insulin (75/25 mix) and variants of insulin detemir (IDet, Det S compact) (Table 3).
Glycemic Outcomes
Primary Outcomes
HbA1c
Gla-100 and other first-generation basal insulins did not differ significantly with respect to HbA1c reduction in five of the seven studies [9, 57, 58, 60, 61], the majority (n = 5) of which were of good quality. However, Gla-100 was found to be more effective than detemir formulations (P < 0.05) [59]. A switch-over study conducted by Malone et al. administered lispro mix (75/25) followed by Gla-100 and compared it with the group that received Gla-100 followed by lispro mix (75/25). The study reported a greater reduction in HbA1c levels in the arm receiving Gla-100 first than those receiving lispro mix (75/25) (− 1 vs. − 0.42; P < 0.001) [62] (Table 3).
Response Rates
Though three studies did not report any significant difference between Gla-100 and other first-generation basal insulins, there were two studies that reported a significantly higher number of Gla-100 receiving patients achieving target HbA1c levels (53 vs. 38%, P = 0.026) and target FPG (58 vs. 46%, P < 0.01) when compared to those receiving IDet [9, 60]. Both of these studies were of good quality. Interestingly, in a switch-over study (poor quality), a greater number of patients receiving lispro mix (75/25), followed by Gla-100 achieved target HbA1c levels (30 vs. 12%, P = 0.002) than those receiving Gla-100 followed by lispro mix (75/25). However, the opposite was true for patients achieving FPG levels with more patients receiving Gla-100 followed by lispro mix (75/25) achieving target FPG levels (51 vs. 34%, P = 0.01)[62]. None of the studies reported data on treatment satisfaction (see Table S2 in the electronic supplementary material for details).
Safety Outcomes
Primary Outcomes
Hypoglycemia Events
No significant difference was observed in hypoglycemic events between patients receiving Gla-100 and other first-generation basal insulins in five studies reporting hypoglycemia events; of which three were of good quality and two were of poor quality. However, one study of good quality reported that Gla-100 was associated with a significantly higher number of hypoglycemic episodes per patient-year when compared to those receiving IDet (4.41 vs. 3.19 patient-years, P = 0.034) [60]. Similarly, a significantly higher number of nocturnal events were observed in patients receiving Gla-100 followed by lispro mix (75/25) than those receiving lispro mix (75/25) followed by Gla-100 (P = 0.002) [62] (Table 5).
Other Outcomes
Gla-100 vs. NPH
Other Glycemic Outcomes
BG Profile
Of the six studies reporting the difference between FPG levels at baseline and at study endpoint, five studies were of good-to-fair quality [15, 17, 19, 22, 25] and one study was of poor quality [20]. Out of these eight studies, Gla-100 resulted in significant FPG reduction in four studies [14‐16, 24] (Table 3).
Glycemic Variability
Total seven studies reported glycemic variability, either in terms of coefficient of variation (CV) [18, 21] or reduction in mean blood glucose values [15, 19, 20, 24, 25]. Of these, four studies were of fair-to-good quality [15, 19, 21, 25], while the remaining three were of poor quality [18, 20, 24]. The study by Mu et al. reported that Gla-100 exhibited better reduction in CV [13.4 (3.6) at baseline to 10.2 (4.2) at the end of study] when compared with NPH (12.9 [4] at baseline to 19.6 [6.1]; P < 0.05) [18]. In a study by Mattia et al., when Gla-100 was followed by NPH, Gla-100 exhibited not only lower BG excursion at 5-h (129.1 vs. 152.8 mg/dL; P < 0.05) but also at 6-h post-meal test (108.5 vs. 154.6 mg/dL; P < 0.01) when compared with NPH insulin [19]. When NPH was followed by Gla-100 in the same study, Gla-100 offered significantly efficient post-prandial glucose control (146.5 [16.7] mg/dL) when compared with NPH (171.2 [24.7] mg/dL) (P < 0.02) [19]. However, the study by Yki-Jarvinen et al. reported no significant difference between CVs of FPG for Gla-100 and NPH [21] (See Table S4 in the electronic supplementary material for details).
Other Safety Outcomes
Weight Change and Insulin Dose Change
Out of the nine studies reporting weight change, seven were of good-to-fair quality [14‐17, 19, 21, 25]. It was observed that Gla-100 and NPH did not differ significantly with respect to weight gain, and the difference was statistically non-significant in five studies. However, significant change in weight gain was reported by two studies and both demonstrated that NPH effectively controls weight gain in insulin-naïve patients with diabetes (P < 0.05; P = 0.01) [14, 17] (Table 5).
Most of the studies (n = 8) did not differ significantly with respect to change in insulin dose between baseline and study endpoint [15, 17, 19‐22, 26]; of which six studies were of fair-to-good quality. However, one study of fair quality reported significant increase in insulin dose from baseline (10 U/day for Gla-100 and NPH) to 47.2 (1.3) U/day for Gla-100 compared with 41.8 (1.3) U/day for NPH (P < 0.005) [25] (Table 5).
Treatment Satisfaction
Eliaschewitz et al. reported a significantly better treatment satisfaction with Gla-100 vs. NPH insulin (P < 0.02). The same study also reported that fewer patients receiving Gla-100 lost time from work or normal activities due to diabetes when compared with those receiving NPH (1.8 vs. 3.3%) [22] (See Table S2 in the electronic supplementary material for details).
Gla-100 vs. Premixed Insulin
Other Glycemic Outcomes
BG Profile
In total, 19 studies reported either FPG or PPG levels at baseline, endpoint, and the mean change values. Gla-100 was found to provide better glucose control for FPG and reported statistically significant reduction in FPG levels in six studies of fair-to-good quality when compared to other premixed insulin regimens (P > 0.0001 to > 0.01) [12, 27, 28, 33, 39, 41]. Significant improvements in the PPG levels were also observed in patients receiving Gla-100 compared to those receiving premixed insulin regimens (P < 0.0001 and < 0.01) in two studies of fair quality [12, 28]. However, a single study (which was of poor quality) reported significantly improved PPG levels with premixed insulin (twice daily) compared with Gla-100 (once daily) (P = 0.001) [30] (Table 3).
Glycemic Variability
Out of six studies reporting insulin initiation comparing treatment difference between Gla-100 and premixed insulins, five were of fair-to-good quality [13, 29, 35, 39, 40]. It was reported that though Gla-100 offers better blood glucose control than human premixed insulin (30% regular, 70% NPH insulin; insulin actraphane HM 30/70) [39], it did not provide as much insulin sensitivity when compared to that of insulin lispro 25/75 BID (9.3 [6.6] vs. 14.4 [10.8], P = 0.020) [13]. Likewise, premixed insulin seemed to offer better postprandial glycemic exposure (~ 25% less for the BIAsp 70/30 group than for the Gla-100 group, 97.4 [90.4] vs. 129.6 [102] mg/dL, P < 0.05) [40] (see Table S4 in the electronic supplementary material for details).
Other Safety Outcomes
Weight Change and Insulin Dose Change
In total, 19 studies reported the body weight either at baseline, post-treatment, or the difference in weights. However, only six have reported a statistical difference between Gla-100 vs. premixed insulins, with Gla-100 unanimously found to be associated with significantly less weight gain (P < 0.001 to < 0.05) in six studies. These studies were of fair-to-good quality [28, 29, 33, 36, 40, 41] (Table 4).
Six studies reporting significantly lesser change in the insulin dose from baseline to endpoint for Gla-100 compared with premixed insulin regimens (P < 0.005 to < 0.05) were of fair-to-good quality; except Kazda et al., which was of poor quality [10, 33, 35, 39‐41]. On the contrary, four studies reported no statistical difference between Gla-100 and premixed insulin dose increment, of which three were of fair-to-good quality [7, 31, 32, 34] (Table 4).
Treatment Satisfaction
Gla-100 exhibited better treatment satisfaction scores than premixed insulins (P < 0.0001 to < 0.05) in three studies that were of fair-to-good quality [12, 28, 29] (see Table S2 in the electronic supplementary material for details).
Gla-100 vs. Second-Generation Basal Insulin
Other Glycemic Outcomes
BG Profile
In total, nine studies comparing second-generation insulin regimens with Gla-100 did not show any statistical difference in reduction in FPG levels. However, one study by Marso et al. [44] reported that in comparison to Gla-100, IDeg caused a significant reduction in FPG levels (P < 0.0001) [44]. None of the studies reported any data regarding PPG levels (Table 3).
Glycemic Variability
Only three studies, which were of good quality, reported data on glycemic variability [46, 48, 51]. Compared to Gla-300, Gla-100 provided lower CV (%) (18.7 [0.5] vs. 18.3 [0.5]) [48]. Similar results were reported in another study wherein lower CV was reported in the Gla-100 group (12.9%) when compared with theIDeg-100 group (14.2%) [46] (see Table S4 in the electronic supplementary material for detail). However, these differences did not reach any statistical significance.
Other Safety Outcomes
Weight Change and Insulin Dose Change
In total, 13 studies reporting changes in body weight for patients receiving either Gla-100 or a second-generation basal insulin were of fair-to-good quality. Nine studies showed no statistical difference between the groups [44‐48, 50‐53]. However, two studies reported that Gla-300 was associated with significantly lower weight gain than Gla-100 (P = 0.003 and 0.015) [8, 49] (Table 5).
Of all the 13 studies reporting a change in insulin dose, only two studies of fair-to-good quality exhibited a significant difference in favor of Gla-100 (P = 0.04 and < 0.05) [44, 49]; whereas three studies reported increased dose of IDeg at the endpoint (P < 0.05) [47, 50, 51] (Table 5).
Treatment Satisfaction
No study exhibited significant difference in the treatment satisfaction scores.
Gla-100 vs. Co-Formulations
Other Glycemic Outcomes
BG Profile
No significant difference was reported for FPG levels between the groups receiving Gla-100 and insulin co-formulations. No data on PPG levels were reported in these studies [54‐56] (Table 3).
Glycemic Variability
Only one study of fair quality reported significantly lower prandial glucose increments, overall and at main evening meal, with IDegAsp once daily than with Gla-100 once daily (P < 0.001) [54] (see Table S4 in the electronic supplementary material for details).
Other Safety Outcomes
Weight Change and Insulin Dose Changes
One study of good quality reported significant weight gain in patients receiving Gla-100 when compared with those receiving insulin co-formulations (4.4 vs. 2.8 kg, P < 0.0001) [55] (Table 5).
The insulin dose changes were similar between the groups receiving Gla-100 and co-formulation groups [54‐56] (Table 5).
Treatment Satisfaction No data were reported regarding treatment satisfaction.
Gla-100 vs. Other First-generation Basal Insulins
Other Glycemic Outcomes
BG Profile
A total of four studies reported FPG reductions; of which three studies were of good quality [9, 60, 61] and one of poor quality [62]. The majority of studies (n = 3) comparing Gla-100 and other first-generation basal insulins did not report significant difference with respect to reduction in FPG levels. The study conducted by Malone et al. administered lispro mix (75/25) followed by Gla-100 and compared it with the group that received Gla-100 followed by lispro (75/25). The study reported a significant difference in favor of the group receiving Gla-100 followed by lispro mix (75/25) (P < 0.007) [62] (Table 3).
Glycemic Variability One study of poor-quality reported data on glycemic variability comparing Gla-100 with other first-generation basal insulins. Compared to Gla-100, the measure of insulin sensitivity was found to be lower with the insulin lispro mixture (23.18 [20.92] vs. 31.44 [23.93]; P = 0.001) in patients receiving Gla-100 followed by lispro mix [62] (see Table S4 in the electronic supplementary material for details).
Other Safety Outcomes
Weight Change and Insulin Dose Change
Out of five studies reporting weight changes, three were of good quality [9, 60, 61] and two were of poor quality [57, 62]. The weight gain was significantly lower in patients receiving Gla-100, as reported in one study (P = 0.001) [62], while the other two studies reported significantly lower weight gain in the IDet group (P < 0.05) [9, 60] (Table 5).
Of the three studies reporting significant differences in increased insulin doses, two were of good quality [9, 60] and one was of poor quality [62]. However, these changes were in favor of Gla-100, which exhibited lower dose change than other insulins (P < 0.0001 to P = 0.0119) [9, 60, 62] (Table 5).
Treatment SatisfactionNone of the studies reported data on treatment satisfaction.
Insulin Intensification
Gla-100 vs. NPH Insulin
Glycemic Outcomes
Primary Outcome
HbA1c
Two studies of fair quality reported data on the change in HbA1c levels. The study by Rosenstock et al. did not report any significant difference in groups receiving Gla-100 along with regular pre-meal insulin, and those taking NPH insulin along with regular insulin. However, a study by Betonico et al. included patients taking two different insulin regimens: Gla-100 OD followed by NPH, both administered along with insulin lispro (group A); and Insulin NPH followed by Gla-100, both co-administered with insulin lispro (group B). The patients in group A reported a significant reduction in HbA1c levels post treatment (P = 0.028) [72, 73] (Table 4).
Response Rates
One study reported the proportion of patients achieving target FPG levels and there was no significant difference in the proportion of patients receiving either Gla-100 (23.6%) or NPH insulin (27.1%) [73] (see Table S3 in the electronic supplementary material for details).
Safety Outcomes
Primary Outcome
Hypoglycemia Events
Both studies reporting hypoglycemia events were of fair quality. Similar proportions of overall hypoglycemic events were observed in patients receiving either Gla-100 or NPH. On the contrary, Gla-100 exhibited a significantly lower number of confirmed nocturnal hypoglycemic events than those receiving NPH (31.3 vs. 40.2%, P = 0.02 and 0.5 vs. 1.5 events/patient, P = 0.047) [72, 73]. Compared to NPH, overall hypoglycemic events and severe hypoglycemia events were relatively fewer in patients receiving Gla-100, but the difference was statistically insignificant (Table 6).
Out of 15 studies reporting the change in HbA1c levels from baseline to the endpoint in patients receiving either Gla-100 or premixed insulins, six were of fair-to-good quality [70, 71, 74‐77]. Three of these 15 studies reported that premixed insulin was able to significantly reduce the HbA1c level towards the endpoint when compared to those receiving Gla-100 [70, 74, 75]; however, in five studies, Gla-100 significantly reduced HbA1c levels [64, 66, 76, 77, 83] (Table 4).
Response Rates
Of the six studies reporting response rates, fourreported statistically significant outcomes. Three of these were of good quality. In two of these studies, significantly fewer patients receiving Gla-100 were able to achieve target HbA1c levels when compared to those receiving premixed mixture (P < 0.005, each) [70, 74]. However, in the remaining two studies, a significantly higher number of patients receiving Gla-100 achieved target HbA1c levels [64, 76] (see Table S3 in the electronic supplementary material for details).
Safety Outcomes
Primary Outcome
Hypoglycemia Events
Out of 14 studies reporting hypoglycemia events, five were of good quality [70, 74‐76, 83]. Only two studies reported statistically significant differences, with a higher (P < 0.05) proportion of overall hypoglycemia events in Gla-100 intensified arm as compared to the group receiving premixed insulin[67, 70]. Further, only two studies showed statistically significant difference in terms of nocturnal hypoglycemia with the patients receiving Gla-100 intensified regimen exhibiting fewer confirmed events of nocturnal hypoglycemia than those receiving premixed insulin [68, 74] (Table 6).
Gla-100 vs. Second-Generation Basal Insulins
Glycemic Outcomes
Primary Outcome
HbA1c
Of the two insulin intensification studies evaluating Gla-100 vs. second-generation basal insulin, only one study reporting the effect on HbA1c reduction between Gla-100 and second-generation basal insulin (Gla-300) was of good quality. Interestingly, both study groups exhibited a similar reduction in HbA1c at study endpoint and the difference was not statistically significant [81]. Further, the study by Hollander et al., which was of poor quality, showed similar HbA1c reduction in both Gla-100 and IDeg treatment arms; the estimated treatment difference was non-significant between Gla-100 and IDeg, suggesting that similar glycemic control can be achieved with Gla-100 and IDeg [80] (Table 4).
Response Rates
Three studies reported data comparing Gla-100 and its second-generation analogues including Gla-300 and IDeg. No difference was observed between groups with respect to number of patients achieving target HbA1c and FPG levels, either with or without hypoglycemic events (see Table S3 in the electronic supplementary material for details).
Safety Outcomes
Primary Outcome
Hypoglycemia Events
No differences were observed in the number of overall hypoglycemic events and severe hypoglycemia between patient groups receiving Gla-100 and Gla-300. However, Gla-100 exhibited more episodes of nocturnal hypoglycemia than corresponding Gla-300 (4.57 vs. 3.32 episodes/patient-year) and the difference was statistically significant (P = 0.0045) [81]. On the contrary, Hollander et al. reported significantly reduced risk of hypoglycemia (overall rate of hypoglycemia: 24% lower; P = 0.011 and nocturnal hypoglycemia: 31% lower; P = 0.016) with IDeg use than with Gla-100 [80] (Table 6).
Gla-100 vs. Co-Formulations
Glycemic Outcomes
Primary Outcome
HbA1c
Only one insulin intensification study comparing Gla-100 vs. co-formulations reported HbA1c reduction; the study was of fair quality. Both Gla-100 and insulin co-formulations (IDegAsp, aspart) exhibited similar HbA1c reduction profiles, and no significant difference was observed between treatment groups [82] (Table 4).
Response Rates
No studies comparing Gla-100 and insulin co-formulations (IDegAsp, aspart) reported data on the response rate.
Safety Outcomes
Primary Outcome
Hypoglycemia Events
No differences were observed in the number of overall hypoglycemic events or severe hypoglycemia events between patient groups receiving Gla-100 and IDegAsp. However, Gla-100 exhibited higher number of confirmed nocturnal hypoglycemia events than corresponding insulin co-formulation group (1.01 vs. 0.6 episodes/patient-year) and the difference was statistically significant (P < 0.05) [82] (Table 6).
Gla-100 vs. other First-Generation Basal Insulins
Glycemic Outcomes
Primary Outcome
HbA1c
Only one study reported HbA1c reduction and the study was of fair quality. A study by Raskin et al. reported that patients receiving Gla-100 in combination with insulin aspart and other OADs were able to significantly reduce the HbA1c levels when compared to patients receiving other basal insulins like IDet with insulin aspart and other OADs (− 1.28 vs.− 1.08, P = 0.035) [78] (Table 4).
Response Rates
No studies comparing Gla-100 and other first-generation basal insulins reported data on response rate.
Safety Outcomes
Primary Outcome
Hypoglycemia Events
Incidence of hypoglycemic events (17.94 vs. 19.30 episodes/PYE) and confirmed nocturnal hypoglycemia (3.38 vs. 4.23 episodes/PYE) and severe hypoglycemic events (0.12 vs. 0.09 episodes/PYE) were comparable between patients receiving IDet and those receiving Gla-100 [78] (Table 6).
Other Outcomes
Gla-100 vs. NPH
Other Glycemic Outcomes
BG Profile
None of the insulin intensification studies reported any data comparing the effect on FPG and PPG levels after administering Gla-100 with NPH.
Glycemic Variability
Glycemic variability was reported in one study of fair quality. No significant difference in glycemic variability was reported in patients taking Gla-100 followed by NPH co-administered with insulin lispro vs. those receiving NPH, followed by Gla-100 co-administered with insulin lispro [72]. However, it was observed that Gla-100 receiving patients spent lower average daily time in hypoglycemia than those receiving NPH. On the other hand, no significant differences were observed in the risk of hypoglycemia between the two groups (see Table S5 in the electronic supplementary material for details).
Other Safety Outcomes
Weight Change and Insulin Dose Change
The study by Rosenstock et al. (2001) (fair quality study) reported a significantly lower weight change in patients receiving Gla-100 when compared to those receiving NPH insulin (0.4 vs. 1.4 kg, P = 0.0007) when administered with regular pre-meal insulins [73] (Table 6).
Change in the insulin dose from baseline to the endpoint was similar in Gla-100 and NPH groups, and no statistical difference was observed in both the studies [72, 73] (Table 6).
Treatment Satisfaction
No data on treatment satisfaction were reported.
Gla-100 vs. Premixed Insulin
Other Glycemic Outcomes
BG Profile
Only three studies, which were of good quality, reported data on FPG profiles [70, 74, 83]. Compared to their premixed counterparts, Gla-100 was found to be associated with significant reduction in the FPG levels from the baseline values in three studies (P < 0.001 each) [66, 74, 83]. Only one study reported PPG profile, which indicated reduction in PPG levels in both the treatment arms (premixed insulin: 287.29–171.54; Gla-100: 281.42–177.52), but the difference was not significant [67] (Table 4).
Glycemic Variability
The BG profile improved in both groups at study end, with more pronounced decline in BG observed in the group receiving premixed insulin than the one receiving Gla-100 (LS mean difference: 3.6 mg/dL [95% CI 0.03–0.4]; P = 0.024) [74] (see Table S5 in the electronic supplementary material for details).
Other Safety Outcomes
Weight Change and Insulin Dose Change Patients receiving Gla-100 or other premixed insulin formulations exhibited similar weight change in a majority of studies; of which three studies were of good quality and one was of poor quality [67, 74, 76, 83]. However, a study conducted by Tinahones et al. reported significantly lower weight change in the Gla-100 group compared to the lispro mix group (0.5 vs. 1.13 kg, P = 0.018), with simultaneous oral administration of OADs [75] (Table 6). Out of 15 studies, two of fair-to-good quality reported no significant change in insulin dose from baseline [71, 75] (Table 6).
Treatment Satisfaction
No data on treatment satisfaction were reported.
Gla-100 vs. Second-generation Basal Insulin
Other Glycemic Outcomes
BG Profile
A study by Riddle et al. reported the effect on FPG levels between Gla-100 and Gla-300. Both groups exhibited similar reduction in FPG levels at study endpoint and the difference was not statistically significant [81]. Another study reporting the effect on FPG levels between Gla-100 and IDeg showed similar reduction in FPG levels [64] (Table 4).
Glycemic Variability
There was no difference in the change of day-to-day variability of pre-injection SMPG between Gla-100 and Gla-300 study groups [81] (see Table S5 in the electronic supplementary material for details).
Other Safety Outcomes
Weight Change and Insulin Dose Change
Similar weight gain was observed in Gla-100 and Gla-300 or IDeg groups at the study endpoint [64, 81]. A gradual increase in insulin dosing was observed in Gla-100 and Gla-300 regimens by the same extent, and no significant difference was observed between the two groups [81]. Hollander et al. reported similar insulin doses in IDeg and Gla-100 groups [80] (Table 6).
Treatment Satisfaction
No data on treatment satisfaction were reported.
Gla-100 vs. Coformulation Insulin
Other Glycemic Outcomes
BG Profile
Gla-100 and IDegAsp exhibited similar FPG reduction profiles, and no significant difference was observed between treatment groups [82] (Table 4).
Glycemic Variability
No studies comparing Gla-100 and insulin co-formulations (IDegAsp) reported data on glycemic variability.
Other Safety Outcomes
Weight Change and Insulin Dose Change
Both Gla-100 and IDegAsp exhibited similar weight gain profiles, and no significant differences were observed between the treatment groups (Table 6).
One study reported data representing the increase in insulin dose between groups receiving Gla-100 and insulin aspart, and compared it with those receiving IDegAsp in combination with other OADs. The insulin dose gradually increased in both the groups. However, a significant increase in insulin dose was observed in patients receiving Gla-100 (34.6–89.3 U/day) than those receiving IDegAsp (35.2–83.4 U/day), and the difference was statistically significant (P < 0.05) [82] (Table 6).
Treatment Satisfaction
No studies comparing Gla-100 and insulin co-formulations (IDegAsp) reported data on treatment satisfaction.
Gla-100 vs. Other First-Generation Basal Insulins
Other Glycemic Outcomes
BG Profile
In BG profile, Gla-100 and IDet exhibited similar FPG profile and no significant difference was observed between the two treatment groups. No studies reported data on the PPG profile (Table 4).
Glycemic Variability
No studies comparing Gla-100 and other first-generation basal insulin reported data on glycemic variability between the two treatment groups.
Other Safety Outcomes
Weight Change and Insulin Dose Change Patients receiving Gla-100 in combination with insulin aspart and OADs exhibited significantly higher weight gain than those receiving IDet along with insulin aspart and OADs (2.7 vs. 1.2, P = 0.001) [78] (Table 6).
Both Gla-100 and IDet exhibited significant increase in insulin dose from the baseline to the endpoint. However, the increase in insulin dose was not statistically significant between the two treatment groups [78] (Table 6).
Treatment Satisfaction
No studies comparing Gla-100 and other basal insulin reported data on treatment satisfaction.
Quality of Studies
Out of 63 RCTs, 22 were of good quality, 18 of fair, and 23 of poor quality. Six observational studies were of good quality and ten observational studies were fair in quality (see Table S6 and S7 in the electronic supplementary material for details).
Primary Outcome Data Summary of Good-Quality Studies
Primary outcome data of the 22 RCTs and six observational studies of good quality have been summarized in Table S8 (see electronic supplementary material for details).
Discussion of Evidence: Implications for Clinical Practice
The present systematic review reflects the current evidence base with regard to the use of Gla-100 in initiation and intensification of insulin therapy, wherein majority of the studies had compared Gla-100 with NPH, premixed and second-generation basal insulins. Overall, the data presented in this review, which included evidence from 79 studies, demonstrated that the initiation or intensification of Gla-100 in patients failing oral or other insulin therapies resulted in improved glycemic outcomes from baseline, with a low risk of hypoglycemia. In the subsequent section, we have tried to appraise the data discussed in this review to address important and practical clinical considerations with the use of Gla-100 in T2DM management.
Anzeige
Glucose-Lowering Ability of Gla-100 vs. Premixed Insulins in Insulin-Naïve Patients with T2DM
The majority of studies in the present review suggested that Gla-100 was better than premixed insulins and comparable to co-formulations in terms of HbA1c-lowering ability. Similar findings were reported in a systematic review and meta-analysis by Rys et al., which revealed a greater mean HbA1c reduction with Gla-100 + OADs vs. premixed insulins twice daily with a weighted mean difference (WMD) of − 0.36% [− 0.54, − 0.18] (− 3.9 mmol/mol [− 5.9; − 2.0])) and associated with a higher chance of reaching target HbA1c (RR = 1.49) [86]. Further, in all six studies that reported statistically significant differences in terms of FPG reduction, Gla-100 was associated with a greater FPG reduction compared to premixed insulins in insulin-naïve T2DM patients (P < 0.0001 to < 0.01) [12, 27, 28, 33, 39, 41]. Though PPG reduction was recorded in three of the head-to-head studies comparing Gla-100 vs. premixed insulins [10, 11, 30], only one showed a statistically significant difference in favor of premixed insulins [30]. The remaining two studies did not detect any statistical difference between either Gla-100 and premixed arms in terms of PPG reduction [11, 30]. Further, our analysis revealed that when patients receiving premixed insulin analogue were switched to Gla-100, there was a significant improvement in all the three glycemic parameters [12, 28]. This would indicate the glucose-lowering ability of Gla-100 in improving overall glycemic control. This evidence belonged to fair-quality studies [12, 28]. These results suggest that targeting basal normoglycemia with Gla-100 ± OADs leads to greater HbA1c and FPG reductions vs. premixed insulins along with mitigating PPG excursions in T2DM patients who are uncontrolled on OADs.
Gla-100 vs. Second-Generation Basal Insulin in Insulin-Naïve Patients with T2DM
When glucose-lowering efficacy was compared between Gla-100 and Gla-300, the majority of studies demonstrated comparability between these two basal insulins in achieving HbA1c and FPG reductions [6, 8, 43, 48, 49]. The data from the EDITION trials revealed comparable glucose-lowering efficacy for Gla-100 and Gla-300, but a significantly lower risk of hypoglycemia, particularly for nocturnal hypoglycemia associated with Gla-300 [69]. Similar observations were revealed in the trial-level meta-analysis conducted by Roussel et al. to obfuscate the limitations of individual trials and facilitate a better understanding of results across the multiple individual trials [69]. In this analysis, the EDITION trials meta-analysis revealed comparable reductions in HbA1c, FPG, and average 24-h SMPG. The risk of confirmed or severe hypoglycemia events was significantly lower with Gla-300 vs. Gla-100, both nocturnally as well as throughout the daytime (P = 0.007 for both) [69]. The recent report from DELIVER 3 study, which was a good-quality evidence, showed a contrasting observation indicating superiority of Gla-300 over Gla-100 in achieving glycemic (HbA1c) reduction [42].
Compared to IDeg, HbA1c-lowering efficacy was comparable with Gla-100 across all studies [44‐47, 50‐53]. However, the trial-level meta-analysis revealed a greater HbA1c reduction with Gla-100 vs. IDeg (P = 0.024) [69]. Further, this trial-level meta-analysis showed a lower risk of confirmed or severe hypoglycemia nocturnally (P = 0.007) and not throughout the day (P = 0.49) with IDeg vs. Gla-100 [69].
Hence, in summary, evidence presented in this review pertaining to the second-generation basal insulins would suggest that their benefit over Gla-100 would only extend to a lower hypoglycemia risk (both nocturnal and any-time) with Gla-300 and a lower nocturnal hypoglycemia risk with IDeg, with a comparable glucose-lowering benefit to Gla-100.
Anzeige
Basal Prandial vs. Premixed Intensification Strategy
As T2DM is a progressive disease, intensification of insulin therapy is inevitable. There exists a wide variation in the guidelines’ recommendations with respect to insulin intensification strategies, which is a challenge for physicians and a major barrier in their decision-making [87, 88]. The data presented in this review revealed that five studies showed significant reduction with Gla-100 than premixed regimens, whereas three out of the 15 intensification studies comparing premixed regimens vs. Gla-100-based insulin regimens revealed a significantly greater HbA1c reduction with premixed intensification regimens. However, two of the nine studies reported a statistically significant higher risk of overall hypoglycemia with premixed intensification regimen vs. Gla-100 intensification regimens, one study reported lower risk of overall hypoglycemia, seven did not show any difference, and the remaining studies did not mention the same. This is in line with the findings of the systematic review and meta-analysis by Rys et al., which have shown that Gla-100-based intensification strategy is similar to premixed intensification regimens both in terms of its HbA1c-lowering ability and hypoglycemia risk [86]. However, the gradual intensification of insulin therapy with basal-plus followed by basal-bolus is considered to mimic physiological insulin secretion more closely compared to premixed regimens [68, 80, 83]. Further, such an approach also helps in acclimatizing patients better to insulin regimens, which in turn may lead to a better chance of acceptance by the patients and therebymore success in routine clinical practice [89‐92].
Strengths and Limitations
Strengths
Previously published secondary studies did not provide a full picture of clinical efficacy and safety of Gla-100 since they were focused exclusively on certain aspects of insulin therapy (for example, only insulin initiation or intensification of insulin treatment) and did not attempt to accrue all the included studies with Gla-100. This review includes a comprehensive and updated list of studies on Gla-100 vs. other insulin formulations for both initiation and intensification, is not limited by study design, and seeks to include a wide range of study designs including RCTs, and prospective and retrospective cohort and observational studies. This provides a comprehensive and up-to-date picture of Gla-100’s use in T2DM management. Additionally, the evidence presented forth in this review has been appraised qualitatively with the intention of drawing the reader’s focus on the fair-to-good quality of evidence with Gla-100.
Limitations
The heterogeneity of the clinical characteristics, complexities of the different insulin treatments, and study designs can confound the conclusions drawn from the data presented here. Moreover, this systematic review did not attempt to quantitatively appraise the data in the form of forest plots, which significantly limits the accuracy and precision of the conclusions.
Conclusions
In conclusion, this systematic literature review revealed that for the primary efficacy parameters studied in this review, Gla-100 insulin regimens may be a better insulin-initiation option compared to premixed insulins and comparable to NPH insulin, other first-generation basal insulins, co-formulations, and second-generation basal insulins. Overall, hypoglycemia risk with Gla-100 insulin (initiation regimens) was lower compared with NPH, premixed, co-formulations, and other first-generation basal insulins, but higher compared to second-generation basal insulins. For intensification of insulin therapy, Gla-100-based stepwise intensification strategy (basal plus to basal bolus) was better compared to other first-generation basal insulin; similar compared to NPH, co-formulations, second-generation basal insulins, and premixed insulins for the primary efficacy parameters. Further in intensification studies, overall hypoglycemia risk with Gla-100 was significantly lower compared with other first-generation basal insulins and comparable to NPH, premixed insulins, co-formulations, and second-generation basal insulins.
Acknowledgements
Funding
This initiative was supported by Sanofi. The medical writing cost of this manuscript and the journal's Rapid Service Fee were paid for by Sanofi. The authors received no honoraria from Sanofi directly or indirectly related to the development of this publication.
Medical Writing, Editorial, and Other Assistance
The authors thank Tejal Vedak from Sqarona Medical Communications LLP (Navi Mumbai) for providing medical writing and technical editing support in the preparation of this manuscript, which was paid for by Sanofi, India.
Anzeige
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Author Contributions
Bipin Sethi, AG Unnikrishnan, Vageesh Ayyar, PK Jabbar, KK Ganguly, Sudhir Bhandari, Ashu Rastogi, Rajarshi Mukherjee, Vivek Sundaram, and Adlyne R Asirvatham contributed to the conception, design, material preparation, data collection, and analysis. Each of the named authors reviewed and critically appraised the manuscript during development and approved the final version for publication.
Disclosures
Bipin Sethi, AG Unnikrishnan, Vageesh Ayyar, PK Jabbar, KK Ganguly, Sudhir Bhandari, Ashu Rastogi, Rajarshi Mukherjee, Vivek Sundaram, and Adlyne R Asirvatham have no conflicts of interest to disclose.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any new studies with human participants or animals.
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus
verfasst von
Bipin Sethi A. G. Unnikrishnan Vageesh Ayyar P. K. Jabbar K. K. Ganguly Sudhir Bhandari Ashu Rastogi Rajarshi Mukherjee Vivek Sundaram Adlyne R. Asirvatham
Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.
Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.
Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.
In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
